Insulet Faces Securities Lawsuit Over Manufacturing and Quality Failures

Throughout 2025 and early 2026, Insulet leadership frequently touted the company's automated production capabilities at its Acton, Massachusetts facility. Management characterized the manufacturing process as a high-yield, medical-grade operation capable of producing millions of complex devices with rigorous safety standards. However, the company's stock price dropped from $236 to $146 per share after two consecutive medical device corrections revealed systemic issues with cannula tears.

The first correction, initiated on March 12, 2026, followed reports of defects in Omnipod 5 devices. While management initially minimized the scope of the problem, a second, broader correction in May 2026 involved approximately 7 million units—roughly 8.5% of the company's 2025 global production—affecting the Omnipod 5, Dash, and Eros lines. Legal counsel for the plaintiffs, Joseph E. Levi, argues that the company’s repeated quality assurances masked known manufacturing deficiencies, prompting analysts at firms like BTIG and Goldman Sachs to raise concerns over the company's transparency and reputation. Investors who purchased shares between February 21, 2025, and May 26, 2026, have until August 31, 2026, to apply for lead plaintiff status in the case filed in the United States District Court for the District of Massachusetts.